Sorry, you need to enable JavaScript to visit this website.

Vaccines Areas Of Interest

Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. A formal notification regarding the status of your application will be sent once a decision is reached. Pfizer support will only be extended upon the execution of a research agreement. For any questions, please send an email to [email protected] .

  • The following areas of research will be considered:
    •    Studies evaluating COVID-19 burden, long-term or secondary consequences of the disease, healthcare resource utilization, direct and indirect costs and impact on QoL, with particular focus on pediatric, adolescents and special populations.
    •    Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake, especially in pediatric, adolescents, minorities and underserved populations.
    •    Epidemiology studies on SARS-CoV-2 variant evolution, specifically impact on transmission and clinical course of disease*

    * NOT including genomic surveillance

    Please note the following*:
    •    Currently, we are not accepting applications for clinical research that studies the safety, immunogenicity, and/or efficacy of Pfizer’s COVID-19 vaccine.
    •    To ensure vaccine availability for the general public, Pfizer is unable to provide COVID-19 vaccine as part of a grant

    *Unless stated otherwise as part of a competitive grant program
     

  • Research areas to be considered for Pfizer support include:

    1. Epidemiology
      1. Clinical disease burden in different:
        1. age cohorts (e.g., adolescents, infants)
        2. settings (e.g., universities, military, mass gathering, travelers)
        3. clinical condition or patient population (e.g., individuals at increased risk of meningococcal disease)
      2. Nasopharyngeal carriage in different age cohorts and settings (examples above)
      3. Disease isolates characterization – genetic characterization, diversity and evolution, across geographic regions and time periods
      4. Understand incidence trends retrospectively and prospectively
    2. Disease impact – individual and community
      1. Short and long-term clinical consequences, complications 
      2. Direct and indirect costs and quality of life, social and psychological parameters
    3. Vaccine impact - in particular age cohort, setting or patient population
      1. Vaccine effectiveness 
      2. Vaccine impact on carriage dynamics – prevalence, transmission, acquisition
      3. Vaccination program impact on disease evolution and health economics
      4. Broader societal value of implementing meningococcal vaccination program
    4. Implementation of vaccination programs or guidelines
      1. Knowledge/awareness, attitudes/perceptions & behaviors/practices
      2. Vaccination preferences
      3. Barriers and potential solutions including potential vaccine platforms
  • Research areas to be considered for funding include:

    1. Studies evaluating the burden of pneumococcal disease and serotype distribution in children or adults or risk groups before, during, or following the implementation of PCV immunization programs, based on one or more of the following presentations:
      • Primary outcomes, including but not limited to
        • Lower respiratory tract infection, including pneumococcal pneumonia and all-cause pneumonia outcomes
        • Invasive Pneumococcal Disease (IPD)
        • Otitis Media in children
      • Secondary outcomes such as exacerbations of chronic underlying medical conditions or long-term sequelae or post hospitalization mortality over the long-term
      • Relationship between serotype distribution by syndrome or carriage (IPD, pneumonia, OM, NPC)
      • Humanistic burden, such as patient-reported outcome measures and quality of life
      • Mechanisms driving changes in serotypes causing disease following PCV introduction.
      • Other outcomes not captured above that may be modified by the introduction of pneumococcal conjugate vaccines 
      • Documentation of PCV impact on pneumococcal disease a population level following vaccine introduction 
    2. Pneumococcal carriage in children or adults prior to, or following, the implementation of PCV immunization programs
      • Carriage prevalence, acquisition, duration or density that use adequate and current methodologies
      • Exploration of novel methods to more accurately describe the carriage burden.
      • Serotype distribution in carriage
      • Pneumococcal carriage in risk groups
      • Documentation of PCV impact on pneumococcal carriage a population level following vaccine introduction 
    3. Association between pneumococcal infection or disease and respiratory viral illnesses such as those due to influenza, RSV, or SARS CoV2 in children or adults
      • The impact of respiratory virus on subsequent pneumococcal disease immunity and risk of respiratory infection 
      • Interaction between pneumococcal carriage / pneumococcal disease and respiratory viral disease viral or pneumococcal disease outcomes 
      • Impact of respiratory virus pandemics and associated non-pharmacologic interventions on pneumococcal disease epidemiology.
    4. Translational research on the molecular epidemiology of pneumococcal disease or carriage and disease pathogenesis
      • Genomic pneumococcal epidemiology and mechanisms of pneumococcal disease pathogenesis
      • Serotype or risk group impact on the above
      • Novel laboratory evaluations to support pneumococcal research
    5. Studies that assess implementation of vaccine programs
      • Strategies to improve vaccine access and uptake with focus the reduction of on equity
      • Understanding factors that impact vaccine uptake


    Research areas not funded

    • Studies on vaccine efficacy, effectiveness or immunogenicity
    • Studies evaluating the serotype distribution in community-acquired pneumonia using Pfizer’s urinary antigen detection test
    • Evaluations of competitor pneumococcal vaccines in isolation
  • COVID-19 Vaccine

    Please visit the COVID-19 Vaccine Grants page to see the areas of interest that will be considered.

    Meningococcal

    Research areas to be considered for Pfizer support include:

    1. Epidemiology
      1. Clinical disease burden in different:
        1. age cohorts (e.g., adolescents, infants)
        2. settings (e.g., universities, military, mass gathering, travelers)
        3. clinical condition or patient population (e.g., individuals at increased risk of meningococcal disease)
      2. Nasopharyngeal carriage in different age cohorts and settings (examples above)
      3. Disease isolates characterization – genetic characterization, diversity and evolution, across geographic regions and time periods
      4. Understand incidence trends retrospectively and prospectively
    2. Disease impact – individual and community
      1. Short and long-term clinical consequences, complications 
      2. Direct and indirect costs and quality of life, social and psychological parameters
    3. Vaccine impact - in particular age cohort, setting or patient population
      1. Vaccine effectiveness 
      2. Vaccine impact on carriage dynamics – prevalence, transmission, acquisition
      3. Vaccination program impact on disease evolution and health economics
      4. Broader societal value of implementing meningococcal vaccination program
    4. Implementation of vaccination programs or guidelines
      1. Knowledge/awareness, attitudes/perceptions & behaviors/practices
      2. Vaccination preferences
      3. Barriers and potential solutions including potential vaccine platforms 
    Pneumococcal disease

    Research areas to be considered for funding include:

    • Studies evaluating the burden of pneumococcal disease and serotype distribution prior to, or following, the implementation of PCV13 immunization programs. In addition, surveillance is conducted following the implementation of PCV10 in order to establish the remaining Burden of Disease (BoD) and serotype distribution:
      • Invasive Pneumococcal Disease (IPD)
      • Pneumonia (CAP, HCAP, HAP)
      • Acute Otitis Media (AOM) (children)
      • Exacerbations of chronic disease (e.g., CLD, CHF, others) either leading to hospitalization or following hospitalization
      • Long term declines in quality of life following pneumococcal syndromes (pneumonia, IPD)
      • Genetic evolution of pneumococci following use of PCV13 or PCV10
    • Nasopharyngeal carriage in children prior to, or following, the implementation of PCV immunization programs
    • Antibiotic resistant S. pneumoniae in children and/or adults prior to, or following, the implementation of PCV immunization programs
    • Association of pneumococcal disease with influenza or other viral illnesses in children and/or adults
    Tick-borne Encephalitis

    Research areas to be considered for Pfizer support include:

    Identification of new TBE-endemic areas, virus-epidemiology

    • Tick surveillance, reservoir animals, human infection, human disease

    Explore Burden of Disease:

    • Characterization of the clinical course or the natural course after infection
    • Diagnostics (e.g., adherence to guidelines, improvement of diagnostics, etc.)
    • Disease and sequelae in children and adults

    New vaccination targets:

    • TBE in travelers
    • TBE in other exposed subjects (i.e., children, elderly, occupation related)